Cerenis Therapeutics : 2017 Financial Calendar

TOULOUSE, France & ANN ARBOR, Mich.--()--Regulatory News:

Cerenis Therapeutics (Paris:CEREN) (FR0012616852 - CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces its financial calendar for 2017.

Events     Date*
  • 2016 Annual Results
    February 17, 2017
  • Cash position and revenue for Q1 2017
    April 20, 2017
  • Annual General Meeting
    June 9, 2017
  • Cash position and revenue for Q2 2017
    July 20, 2017
  • 2017 Half Year Results
    September 12, 2017
  • Cash position and revenue for Q3 2017
    October 26, 2017
  • Cash position and revenue for Q4 2017
    January 25, 2018

The Company will be in “quiet period” from 02/02/17 to 17/02/17.

* Indicative dates which may be subject to change. With some exceptions, press releases are distributed after the financial markets closure.

About Cerenis Therapeutics: www.cerenis.com
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.

Since its inception in 2005, the Company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

About CER-001
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Previous Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.

About CER-209
CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor that is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). CER-209 is a specific agonist of the P2Y13 receptor and does not interact with the P2Y12 receptor. In preclinical studies CER-209 promotes HDL recognition by the liver and increases Reverse Lipid Transport (RLT), thereby impacting atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER-209 may also offer a new mechanism for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

Contacts

Cerenis
Jean-Louis Dasseux, Tel: +33 (0)5 62 24 09 49
CEO
info@cerenis.com
or
LHA
Investor relations (U.S.)
Kim Golodetz, Tel: +1 212 838 3777
kgolodetz@lhai.com
or
NewCap
Investors relations (Europe)
Emmanuel Huynh/Louis-Victor Delouvrier, Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu
or
RooneyPartners
Media relations (U.S.)
Marion Janic, Tel: +1 212 223 4017
mjanic@rooneyco.com
or
NewCap
Media relations (Europe)
Nicolas Merigeau, Tel: +33 (0)1 44 71 94 98
cerenis@newcap.eu

Contacts

Cerenis
Jean-Louis Dasseux, Tel: +33 (0)5 62 24 09 49
CEO
info@cerenis.com
or
LHA
Investor relations (U.S.)
Kim Golodetz, Tel: +1 212 838 3777
kgolodetz@lhai.com
or
NewCap
Investors relations (Europe)
Emmanuel Huynh/Louis-Victor Delouvrier, Tel: +33 (0)1 44 71 98 53
cerenis@newcap.eu
or
RooneyPartners
Media relations (U.S.)
Marion Janic, Tel: +1 212 223 4017
mjanic@rooneyco.com
or
NewCap
Media relations (Europe)
Nicolas Merigeau, Tel: +33 (0)1 44 71 94 98
cerenis@newcap.eu